Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 27

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 27
---
 the 2 anniversary thereof, (b) 85% received from the 2 anniversary of the Closing date until the 4 anniversary of the Closing date, (c) 80% received from the 4 anniversary of the Closing date until the 4 anniversary of the Closing date, and (d) 75% received from the 6 anniversary of the Closing date until the 10 anniversary of the Closing date; (iii) 100% of the net proceeds received by the 10 anniversary of the Closing date for any license or
disposition of the Company’s product candidates and/or intellectual property related to its RP-1664 program, RP-3500 (camonsertib) program, or any other license or
disposition of the Company’s product candidates or research programs if such license or disposition is entered into prior to the Closing date; (iv) 100% of the net proceeds received by the 10th anniversary of the Closing date for any license
or disposition of the Company’s Polq program, RP-3467, to any person with whom negotiations were initiated prior to the Closing date; (v) 50% of the net
proceeds received by the 10 anniversary of the Closing date for any license or disposition of the Company’s product candidates and/or intellectual property that occurs within
10 years following the Closing date if such license or disposition is entered into following the Closing Date; and (vi) 100% of the net proceeds received by the 10 anniversary of the
Closing date by the Company or Repare Therapeutics USA, Inc. from any Governmental Entity on account of investment tax credits, reimbursements or refunds, in each case, to the extend attributable to the period (or portion thereof) prior to the
Closing.

The right to the contingent payments contemplated by the CVR Agreement is a contractual right only and will not be transferable,
except in the limited circumstances specified in the CVR Agreement.

Expenses and Expense Reimbursement

All out-of-pocket expenses incurred in connection with the
Agreement, the Arrangement and the other transactions contemplated by the Agreement will be paid by the party incurring such fees or expenses, whether or not the Arrangement is consummated, with certain exceptions expressly set forth in the
Agreement. If the Agreement is terminated in certain circumstances, a Termination Payment will be payable by the Company.

10

Delisting of the Common Shares

The Common Shares are listed on Nasdaq under the trading symbol “RPTX